CD70-targeted PET/ CT in the Diagnosis of Malignant Cancers
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Aged 18-80 year-old and of either sex；
• Histologically confirmed diagnosis of renal cancer (especially ccRCC)/lymphoma/NPC or suspected renal cancer/lymphoma/NPC by diagnostic imaging;
• Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.
Locations
Other Locations
China
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITING
Shanghai
Contact Information
Primary
Weijun Wei, Ph.D. & M.D.
wwei@shsmu.edu.cn
15000083153
Time Frame
Start Date: 2024-12-23
Estimated Completion Date: 2026-12-23
Participants
Target number of participants: 300
Treatments
Experimental: CD70-targeted immunoPET imaging
Enrolled patients will undergo a CD70-targeted immunoPET/CT scanning.
Related Therapeutic Areas
Sponsors
Leads: RenJi Hospital